EVERSANA’s Post

Read the article: https://ow.ly/bEqE50ShpNQ Our Value & Evidence team at EVERSANA, in collaboration with other HEOR industry experts, has critically reviewed and synthesized worldwide Indirect Treatment Comparison (#ITC) guidelines. Considering the challenges of head-to-head #clinicaltrials, ITCs provide valuable insights into clinical effectiveness. These insights help regulators and reimbursement agencies make informed decisions, improving patient access to novel treatments. Recent methodological advancements have led to global guidelines outlining jurisdiction-specific methodology and best practices. This comprehensive #literaturereview highlights key ITC techniques for objective analyses and ascertains the circumstantial suitability of ITCs as a source of comparative evidence for healthcare interventions. Krista Tantakoun, Christopher Olsen, Fatemeh Mirzayeh Fashami, Imtiaz Samjoo and Chris Cameron

Confused by the new German cost-containment bill? Join Lumanity's • Suzette Matthijsse, PhD at #ISPOREurope where she will deliver a case study exploring the most significant implications for pharmaceutical pricing and reimbursement in Germany following the approval of the cost-containment law and how the new bill interacts with the new European Regulation on HTA. Find out more on our website: #HEOR #HealthEconomics #OutcomesResearch #HTA #RWE

Real-world data is shaping the future of healthcare. Its integration into clinical research offers new possibilities for improving patient outcomes and advancing medical knowledge.

Real-world data is shaping the future of healthcare. Its integration into clinical research offers new possibilities for improving patient outcomes and advancing medical knowledge.

Real-world data is shaping the future of healthcare. Its integration into clinical research offers new possibilities for improving patient outcomes and advancing medical knowledge.

In the biopharma company of today, data is the currency that fuels innovation, drives decision-making and shapes critical clinical outcomes. However, are we truly harnessing its power, or are we merely swimming in an ocean of untapped potential?   Based on the results of PA Consulting's latest research into the perceptions and attitudes of clinical trials of US consumers, it’s clear there is a huge opportunity for #biopharma to leverage data to accelerate and enhance clinical trials.   As an example, a surprising 64% of US consumers we surveyed said they would be happy to share their health data, across studies, to aid clinical research. Discover more insights like this, and what this means for trial design and study optimization in our latest report https://lnkd.in/e_yQrJWP Congratulations to the team for building these insights including Charlie Paterson, George Botsakos, Van Dinh, Kieran Reals and Simon Bates . Let me know if you want to learn more about how we’re helping biopharma companies reimagine clinical research. #Clinicalinnovation #clinicaltrials

Want to leverage Real World Evidence (RWE) for better decision-making and market success? Check out this article comparing existing RWE guidelines to uncover the immense potential of RWE in today's healthcare landscape. From drug development to market access, sales and marketing, and medical functions, RWE is transforming the industry by providing valuable insights and evidence. Discover how companies like EVERSANA are utilizing RWE to inform research decisions, accelerate time to market, communicate economic value, and more. Read the article here: https://lnkd.in/gfjebwzT #RealWorldEvidence #LifeScienceIndustry #DataDrivenDecisions #HealthcareInnovation

Attending ISPOR? Make sure you also register for the Patient-Centered Research Summit on Sunday 5 May. Don’t miss important discussions on impactful patient engagement and patient experience data collection to elevate patient outcomes. The discipline of patient-insight-driven medicines development is recognized a vital driver of innovation. By encouraging the measurement of patient engagement, we can understand the areas of greatest impact – to support meaningful focus, empowering patient advisors to make a difference and supporting sustainable value generation for the industry.   At the ISPOR Patient-Centered Research Summit, I will discuss our Patient Engagement Impact Measurement Framework that we co-created with a patient council. A standardized approach across the pharmaceutical industry would support evidence generation and best practice sharing, so join this session to see how you could adapt and apply this approach to your own work. You’ll also hear examples of the value of patient input into clinical trials. Hope to see you there, if not, get in touch to request the presentation. https://ow.ly/LGtr50QRuuB #ISPORSummit #healthcare #PatientEngagement #PatientCenteredResearch

Tune in next week to learn more about the struggles as well as the successes that organizations in the Life Sciences industry have experienced with their processes to generate insights from big data. Each webinar is tailored, respectively, to Clinical Development, Commercial, and HEOR. #onekomodo

It will come as no surprise to anyone in the healthcare space that doctors today are under an inordinate amount of pressure. They are managing more, in less time, while trying to keep up with treatment information that is out of date faster than they can learn it.   In this unsustainably busy post-COVID world, how can pharma best reach out to and educate doctors about new treatments? We have surveyed 900 doctors in five European countries (France, Germany, Italy, Spain and the UK) to understand today’s doctors and how they consume information. Our distilled data insights white paper provides effective actions to help pharma engage meaningfully with today’s unprecedentedly busy physicians. #pharma #HCPs #hcpengagement #pharmamarketing https://lnkd.in/eG26civ6